SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Developing a human-based stem cell model for reproductive toxicity

Developing a high-throughput human-based assay for male reproductive toxicity to enhance drug safety testing and reduce reliance on animal models.

Subsidie
€ 150.000
2024

Projectdetails

Introduction

Environmental factors and chemicals are thought to be one cause of declining male fertility. Reproductive toxicity is becoming a major public health problem. Currently, new pharmacological or chemical compounds are tested in animals for their effects on reproduction before entering the market. This risk assessment is essential but time-consuming, expensive, and is not always predictive in humans since animals have different reproductive characteristics and physiology. A validated and qualified human system to assess reproductive toxicity would be invaluable in addressing this conundrum between regulatory requirements and true relevance.

Project Overview

Through my ERC-CoG, I have built a large repository of knowledge and developed robust technology on human in vitro gametogenesis, more specifically on how to generate male gamete progenitors from human pluripotent stem cells. This, together with my bioinformatics know-how, makes me exceptionally well-placed to optimize a human-based high-throughput screening assay for male reproductive toxicity for use by the private sector in filing reproductive safety data to the regulatory authorities.

ReproTox Assay Development

This ReproTox assay will be further optimized by:

  1. Increasing throughput
  2. Standardizing measurements

Additionally, it will be integrated with a software innovation, including a machine learning algorithm to automate quantification and a web tool. Before we carry out a pilot screen using FDA-approved spermatotoxic compounds, we will conduct market research to define the commercialization route.

Expected Outcomes

Reducing the number of compounds that show male reproductive toxicity at very early stages of drug development will contribute to an effective first-tier toxicity screening. This will not only provide standard protocols for:

  • Quantitative
  • Rapid
  • Cost-effective
  • High-throughput
  • Scalable
  • Reproducible toxicity testing

But also reduce, and perhaps eventually replace, animal use. ReproTox will ultimately lead to economic, societal, environmental, health, and ethical benefits.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-8-2024
Einddatum31-1-2026
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • ACADEMISCH ZIEKENHUIS LEIDENpenvoerder

Land(en)

Netherlands

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

SAfeguarding female FERtility -development of human-relevant in vitro tools for reproductive toxicity

SAFER aims to develop innovative, animal-free assays for assessing reproductive toxicity in women, using advanced technologies to identify harmful chemicals and promote safer environments.

ERC Consolid...€ 2.000.000
2024
Details

Representative, Reliable and Reproducible in vitro Models of the Human Testes

The project aims to develop a reliable preclinical model of human testes using tailored hydrogels to improve male infertility treatments through high-throughput experimentation and automated analysis.

ERC Starting...€ 1.499.980
2022
Details

Human blastoids: a drug discovery platform for women’s reproductive health

BLASTOID-DISCOVERY aims to utilize human blastoids as a scalable and ethical model for drug discovery to enhance women's reproductive health and reduce development costs.

ERC Proof of...€ 150.000
2023
Details

Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian Embryogenesis

Develop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling.

ERC Consolid...€ 2.000.000
2023
Details

Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotency

The project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies.

ERC Advanced...€ 2.500.000
2023
Details
ERC Consolid...

SAfeguarding female FERtility -development of human-relevant in vitro tools for reproductive toxicity

SAFER aims to develop innovative, animal-free assays for assessing reproductive toxicity in women, using advanced technologies to identify harmful chemicals and promote safer environments.

ERC Consolidator Grant
€ 2.000.000
2024
Details
ERC Starting...

Representative, Reliable and Reproducible in vitro Models of the Human Testes

The project aims to develop a reliable preclinical model of human testes using tailored hydrogels to improve male infertility treatments through high-throughput experimentation and automated analysis.

ERC Starting Grant
€ 1.499.980
2022
Details
ERC Proof of...

Human blastoids: a drug discovery platform for women’s reproductive health

BLASTOID-DISCOVERY aims to utilize human blastoids as a scalable and ethical model for drug discovery to enhance women's reproductive health and reduce development costs.

ERC Proof of Concept
€ 150.000
2023
Details
ERC Consolid...

Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian Embryogenesis

Develop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling.

ERC Consolidator Grant
€ 2.000.000
2023
Details
ERC Advanced...

Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotency

The project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies.

ERC Advanced Grant
€ 2.500.000
2023
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Cultivating hope one star sperm at a time

Spermotile aims to revolutionize male infertility treatment by providing an automated, AI-driven sperm selection platform that enhances ART success rates and reduces costs for clinics and patients.

EIC Transition€ 2.499.906
2025
Details

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development

Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.

EIC Accelerator€ 2.499.831
2024
Details

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

EIC Pathfinder€ 4.475.946
2022
Details

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition€ 1.457.500
2023
Details

Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.

SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market.

EIC Transition€ 786.875
2022
Details
EIC Transition

Cultivating hope one star sperm at a time

Spermotile aims to revolutionize male infertility treatment by providing an automated, AI-driven sperm selection platform that enhances ART success rates and reduces costs for clinics and patients.

EIC Transition
€ 2.499.906
2025
Details
EIC Accelerator

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development

Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.

EIC Accelerator
€ 2.499.831
2024
Details
EIC Pathfinder

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

EIC Pathfinder
€ 4.475.946
2022
Details
EIC Transition

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition
€ 1.457.500
2023
Details
EIC Transition

Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.

SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market.

EIC Transition
€ 786.875
2022
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.